FDA Approves Gene Therapies Casgevy, Lyfgenia for Sickle Cell Disease
The FDA has approved Casgevy and Lyfgenia, the first cell-based gene therapies for the treatment of sickle cell disease in patients 12 years of age and older.
Source: empr.com
Page 23 - Boxed Warning News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Boxed Warning. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Boxed Warning Today - Breaking & Trending Today
FDA Approves Gene Therapies Casgevy, Lyfgenia for Sickle Cell Disease
The FDA has approved Casgevy and Lyfgenia, the first cell-based gene therapies for the treatment of sickle cell disease in patients 12 years of age and older.
Source: clinicaladvisor.com
Prescribing Red Flags And Suspicious Controlled Substance Orders: Current Cautionary Tales - Healthcare
Separate decisions by federal district courts in Texas and Puerto Rico in the past two months provide cautionary tales for every pharmacy and wholesale distributor dispensing...
Source: mondaq.com
Marius Pharmaceuticals Announces KYZATREX® (CIII testosterone undecanoate capsules) HERO Campaign, Empowering Men To 'Be the Hero of Your Life Again'
/PRNewswire/ -- Marius Pharmaceuticals, a pharmaceutical company focused on developing innovative therapies for testosterone deficiency, today announces the...
Source: prnewswire.com
Food And Drug Administration Grants Two New Label Changes To Tirosint®-Sol (Levothyroxine Sodium) Or
New FDA-approved label updates offer patients more flexible administrationPARSIPPANY, N.J.--(BUSINESS WIRE)--The U.S. Food and Drug Administration (FDA) has approved two new changes to the label of Tirosint-SOL (levothyroxine sodium) oral solution, a unique formulation of levothyroxine (LT4) for the treatment of hyp...
Source: pharmiweb.com